241 related articles for article (PubMed ID: 27013965)
1. Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity.
Nixon-Abell J; Berwick DC; Grannó S; Spain VA; Blackstone C; Harvey K
Front Mol Neurosci; 2016; 9():18. PubMed ID: 27013965
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling.
Berwick DC; Javaheri B; Wetzel A; Hopkinson M; Nixon-Abell J; Grannò S; Pitsillides AA; Harvey K
Mol Neurodegener; 2017 Jan; 12(1):9. PubMed ID: 28103901
[TBL] [Abstract][Full Text] [Related]
3. L'RRK de Triomphe: a solution for LRRK2 GTPase activity?
Nixon-Abell J; Berwick DC; Harvey K
Biochem Soc Trans; 2016 Dec; 44(6):1625-1634. PubMed ID: 27913671
[TBL] [Abstract][Full Text] [Related]
4. LRRK2 N551K and R1398H variants are protective in Malays and Chinese in Malaysia: A case-control association study for Parkinson's disease.
Gopalai AA; Lim JL; Li HH; Zhao Y; Lim TT; Eow GB; Puvanarajah S; Viswanathan S; Norlinah MI; Abdul Aziz Z; Lim SK; Tan CT; Tan AH; Lim SY; Tan EK; Ahmad Annuar A
Mol Genet Genomic Med; 2019 Nov; 7(11):e604. PubMed ID: 31487119
[TBL] [Abstract][Full Text] [Related]
5. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
[TBL] [Abstract][Full Text] [Related]
6. Identification of Targets from LRRK2 Rescue Phenotypes.
Toh J; Chua LL; Ho P; Sandanaraj E; Tang C; Wang H; Tan EK
Cells; 2021 Jan; 10(1):. PubMed ID: 33466414
[TBL] [Abstract][Full Text] [Related]
7. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
[TBL] [Abstract][Full Text] [Related]
8. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
Ross OA; Soto-Ortolaza AI; Heckman MG; Aasly JO; Abahuni N; Annesi G; Bacon JA; Bardien S; Bozi M; Brice A; Brighina L; Van Broeckhoven C; Carr J; Chartier-Harlin MC; Dardiotis E; Dickson DW; Diehl NN; Elbaz A; Ferrarese C; Ferraris A; Fiske B; Gibson JM; Gibson R; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lesage S; Lin CH; Lynch T; Maraganore DM; Mellick GD; Mutez E; Nilsson C; Opala G; Park SS; Puschmann A; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Theuns J; Tomiyama H; Uitti RJ; Valente EM; van de Loo S; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Farrer MJ;
Lancet Neurol; 2011 Oct; 10(10):898-908. PubMed ID: 21885347
[TBL] [Abstract][Full Text] [Related]
9. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
10. G2385R and I2020T Mutations Increase LRRK2 GTPase Activity.
Ho DH; Jang J; Joe EH; Son I; Seo H; Seol W
Biomed Res Int; 2016; 2016():7917128. PubMed ID: 27314038
[TBL] [Abstract][Full Text] [Related]
11. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
Tsika E; Moore DJ
Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways.
Sancho RM; Law BM; Harvey K
Hum Mol Genet; 2009 Oct; 18(20):3955-68. PubMed ID: 19625296
[TBL] [Abstract][Full Text] [Related]
13. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
Nguyen AP; Moore DJ
Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
[TBL] [Abstract][Full Text] [Related]
14. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
[TBL] [Abstract][Full Text] [Related]
15. Lrrk2 modulation of Wnt signaling during zebrafish development.
Wint JM; Sirotkin HI
J Neurosci Res; 2020 Oct; 98(10):1831-1842. PubMed ID: 32623786
[TBL] [Abstract][Full Text] [Related]
16. A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity.
Dusonchet J; Li H; Guillily M; Liu M; Stafa K; Derada Troletti C; Boon JY; Saha S; Glauser L; Mamais A; Citro A; Youmans KL; Liu L; Schneider BL; Aebischer P; Yue Z; Bandopadhyay R; Glicksman MA; Moore DJ; Collins JJ; Wolozin B
Hum Mol Genet; 2014 Sep; 23(18):4887-905. PubMed ID: 24794857
[TBL] [Abstract][Full Text] [Related]
17. A Comprehensive Analysis of Population Differences in
Shu L; Zhang Y; Sun Q; Pan H; Tang B
Front Aging Neurosci; 2019; 11():13. PubMed ID: 30760999
[No Abstract] [Full Text] [Related]
18. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
20. The G2385R risk factor for Parkinson's disease enhances CHIP-dependent intracellular degradation of LRRK2.
Rudenko IN; Kaganovich A; Langston RG; Beilina A; Ndukwe K; Kumaran R; Dillman AA; Chia R; Cookson MR
Biochem J; 2017 Apr; 474(9):1547-1558. PubMed ID: 28320779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
